Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 190 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2014', provides an overview of the Gastrointestinal Stromal Tumor (GIST)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastrointestinal Stromal Tumor (GIST) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Gastrointestinal Stromal Tumor (GIST) Overview 9
Therapeutics Development 10
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview 10
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis 11
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies 12
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes 15
Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies 19
Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes 20
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 21
Eli Lilly and Company 21
GlaxoSmithKline plc 22
Takeda Pharmaceutical Company Limited 23
Novartis AG 24
Astex Pharmaceuticals, Inc. 25
Bayer AG 26
Ariad Pharmaceuticals, Inc. 27
Synta Pharmaceuticals Corp. 28
Chipscreen Biosciences Ltd 29
Ambit Biosciences Corporation 30
Semafore Pharmaceuticals, Inc. 31
Deciphera Pharmaceuticals, LLC 32
AB Science 33
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 40
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
regorafenib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
masitinib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
nilotinib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
masitinib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
motesanib diphosphate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
olaratumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ponatinib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
AT-13387 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ganetespib - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
dovitinib lactate - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
crenolanib besylate - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
luminespib - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
(dabrafenib + trametinib) - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
pazopanib hydrochloride - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
binimetinib - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
TH-302 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
SF-1126 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
CS-2164 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Vaccine Targeting NY-ESO-1 for Oncology - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
buparlisib hydrochloride - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
X-82 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
quizartinib - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
DCC-2618 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Small Molecules Targeting c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Gastrointestinal Stromal Tumor (GIST) - Recent Pipeline Updates 112
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 178
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 179
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 180
Featured News & Press Releases 180
Jun 27, 2014: Regorafenib from Bayer Recommended for Approval in the European Union for the Treatment of Gastrointestinal Stromal Tumors 180
Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors 181
Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican 182
Oct 18, 2013: Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours, A Rare Form Of Sarcoma 183
Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig 184
Sep 12, 2013: Bayer to Present Data on Regorafenib at the European Cancer Congress 2013 185
Sep 05, 2013: Bayer's Regorafenib Submitted for European Marketing Authorization for the Treatment of Gastrointestinal Stromal Tumors 186
Aug 20, 2013: Bayer's Stivarga Approved for the Treatment of Patients with Gastrointestinal Stromal Tumors in Japan 187
Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors 187
Jun 04, 2013: IPAB Sets Aside Patent Revocation Order On Pfizer's Anti-Cancer Drug Sutent 188
Appendix 189
Methodology 189
Coverage 189
Secondary Research 189
Primary Research 189
Expert Panel Validation 189
Contact Us 190
Disclaimer 190

List of Tables
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2014 10
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eli Lilly and Company, H2 2014 21
Gastrointestinal Stromal Tumor (GIST) - Pipeline by GlaxoSmithKline plc, H2 2014 22
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 23
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H2 2014 24
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 25
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Bayer AG, H2 2014 26
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2014 27
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Synta Pharmaceuticals Corp., H2 2014 28
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H2 2014 29
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ambit Biosciences Corporation, H2 2014 30
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Semafore Pharmaceuticals, Inc., H2 2014 31
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 32
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science, H2 2014 33
Assessment by Monotherapy Products, H2 2014 34
Assessment by Combination Products, H2 2014 35
Number of Products by Stage and Target, H2 2014 38
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 45
Number of Products by Stage and Molecule Type, H2 2014 47
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Recent Pipeline Updates, H2 2014 112
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2014 178
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2014 179